Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Insider Carole Huntsman Sells 347 Shares of Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) insider Carole Huntsman sold 347 shares of the company’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $335.24, for a total value of $116,328.28. Following the transaction, the insider now directly owns 10,438 shares of the company’s stock, valued at $3,499,235.12. This represents a 3.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Madrigal Pharmaceuticals Stock Performance

NASDAQ MDGL opened at $310.92 on Tuesday. The stock has a market cap of $6.78 billion, a PE ratio of -12.40 and a beta of -0.36. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98. The firm has a 50-day moving average of $314.37 and a 200-day moving average of $273.95. Madrigal Pharmaceuticals, Inc. has a 52-week low of $168.25 and a 52-week high of $368.29.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($4.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.94) by $2.02. The firm had revenue of $62.18 million for the quarter, compared to the consensus estimate of $34.60 million. During the same quarter in the prior year, the firm earned ($5.34) EPS. On average, sell-side analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.55 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on MDGL. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Madrigal Pharmaceuticals in a research report on Wednesday, November 20th. StockNews.com upgraded shares of Madrigal Pharmaceuticals to a “sell” rating in a report on Saturday, October 12th. Oppenheimer decreased their target price on shares of Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. HC Wainwright boosted their price target on shares of Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Tuesday, January 14th. Finally, JMP Securities restated a “market outperform” rating and issued a $427.00 price objective on shares of Madrigal Pharmaceuticals in a report on Friday, January 10th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $351.67.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MDGL. Braidwell LP acquired a new position in shares of Madrigal Pharmaceuticals during the 3rd quarter worth approximately $39,010,000. Eagle Asset Management Inc. acquired a new position in shares of Madrigal Pharmaceuticals during the 3rd quarter worth $6,875,000. Intech Investment Management LLC bought a new position in shares of Madrigal Pharmaceuticals in the third quarter worth about $1,280,000. Vestal Point Capital LP bought a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at approximately $6,367,000. Finally, Blueshift Asset Management LLC bought a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter valued at $393,000. Institutional investors own 98.50% of the company’s stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.